
KRAS-targeting pancreatic cancer drug boosts survival, reaches Charleston patients
A Phase 3 trial showed daraxonrasib, a KRAS-targeting therapy for metastatic pancreatic cancer, nearly doubles median survival (about 13.2 months vs 6.6) and is moving into expanded-access programs, with Terri Truere in Charleston among the first patients in the area to receive it ahead of FDA approval. The drug is not yet approved, but more SC sites are preparing to offer it; it carries notable side effects such as mouth sores and rash, and access remains limited. Doctors see promise that KRAS targeting could improve outcomes and potentially expand surgical eligibility in some patients.

